CMS released the Calendar Year 2027 Physician Fee Schedule (PFS) Proposed Rule on July 14, 2026 — right on its historical mid-July schedule. The rule proposes a net payment cut for most physicians and introduces two structural changes to E/M and practice expense methodology that will ripple through every specialty’s billing model. The public comment period closes September 14, 2026.
The proposed baseline cut flows from two forces: the 2.5% bonus Congress provided for CY 2026 expires automatically at year-end, and the statutory update formula adds only +0.75% (APM) / +0.25% (non-APM) — nowhere near enough to offset the expiration. This is the first fee schedule cycle since 2020 where Congress cannot count on a broad sustainable-growth-rate fix consensus. If Congress does nothing before year-end, the conversion factor drops January 1, 2027.
CMS proposes that when a separately identifiable office/outpatient E/M is furnished by the same physician on the same day as a 0-, 10-, or 90-day global procedure, the most expensive service is paid at 100% and all other services are paid at 50%. This is direct revenue compression for multi-service encounters. High-volume specialties — orthopedics, general surgery, cardiology — regularly bill this combination. Practices should model the dollar impact now, before commenting or adjusting scheduling protocols.
CMS is proposing to reduce reliance on AMA specialty-specific practice expense (PE) per-hour surveys, citing historically low response rates and data discrepancies. PE RVUs will shift toward inputs that favor specialties with stronger survey participation — potentially disadvantaging smaller specialty groups and independent practices that have historically been underrepresented in AMA survey cohorts.
The CY 2026 2.5% Congressional bonus expires automatically at year-end. Without Congressional action, the CY 2027 conversion factor drops by 1.68% for non-APM physicians on January 1, 2027. Model this cut against your current payer mix now — practices heavily weighted toward Medicare fee-for-service will feel it most acutely.
The Medicare Advantage denial crisis reached a tipping point in 2026. At least 23 major health systems have terminated MA contracts, an estimated 2.9 million MA enrollees have been forced into new plans following a spike in plan exits, and the denial rate data is stark: MA plans now deny approximately 17% of all submitted claims — more than double the 8% denial rate under traditional Medicare. PA denials specifically have surged 4.8% year-over-year.
When patients are forced into new MA plans, prior authorizations from the old plan do not transfer. Practices that authorized services under one plan are now seeing:
| Payer | July 2026 Status | Practice Action |
|---|---|---|
| UnitedHealthcare / NYP | Commercial members in-network through July 31 only — negotiations ongoing; MA exit already effective July 1 | Check patient commercial plan status daily through month-end; MA patients out-of-network now |
| Aetna | ~90 MA plans discontinued across 34 states for 2026, mostly PPOs | Audit MA patients for new plan assignment; re-obtain PAs as needed before rendering services |
| Humana | Multiple health system exits throughout 2026 creating patient-migration waves | Run roster audit monthly; identify patients whose PA was obtained under a Humana MA plan that may have exited |
Prior authorizations obtained under an exiting MA plan do NOT automatically transfer to the patient’s new plan. Services already approved and scheduled under the old authorization may be rendered and then denied because the patient is now on a different plan. Implement a protocol to verify current MA plan enrollment at every patient check-in — not just at annual registration — for the remainder of 2026.
The global agentic AI in healthcare market is projected to grow from $1.83 billion in 2026 to $19.71 billion by 2034, a 34.61% CAGR. In revenue cycle specifically, agentic AI holds 20.8% market share within the broader AI healthcare sector — the largest single segment. But “agentic” covers a wide spectrum. Here is what is actually deployable in your billing operation this quarter, vs. what is still 12–24 months out.
Waystar remains the most aggressive mover in agentic RCM, fueled by its Google Cloud partnership — showcasing 50+ AI and automation use cases across its unified Fusion architecture. Adonis achieved 4x revenue growth in 2025–2026, the breakout RCM startup story of the cycle. FinThrive’s Denials and Underpayment Analyzer delivered nearly $1 million in additional cash within 90 days in one deployment, combined with a 2.5% denial rate reduction.
McKinsey’s “Agentic AI and the Race to a Touchless Revenue Cycle” report projects Level 4 systemic automation in two to three years — but notes the revenue cycle has too many unstructured decision points and payer-policy dependencies for full autonomy today. The optimal 2026 strategy is progressive automation of narrow, well-defined tasks with human oversight at clinical-judgment decision points.
Three coding timelines converge this week, and practices behind on any of them will see claim rejections before Q4. The combined impact: HCPCS code set is live-updated quarterly (verify your system has loaded Q3), CPT coding is previewing major 2027 changes, and FY 2027 ICD-10-CM codes take effect in 11 weeks.
Unlike CPT codes (updated January 1 only), HCPCS Level II is updated quarterly. Code additions, deletions, and coverage policy changes can take effect immediately at each quarter start. Your EHR/PM vendor must have loaded the Q3 update — missing HCPCS updates generate claim rejections that surface as coding errors but are actually system synchronization failures. Contact your vendor to confirm the update was applied.
The July 2026 CPT Assistant edition focuses on preparation for significant 2027 labor and delivery CPT code restructuring. Obstetric and delivery codes are among the most frequently misapplied codes in specialty billing. The 2027 restructuring is expected to require documentation workflow changes — not just code crosswalk mapping. OB/GYN practices and hospitalists who handle deliveries should begin engaging their coding teams now.
Confirm with your billing system vendor that HCPCS Q3 2026 updates are loaded. If they are not, claims submitted after July 1 may be using expired or deleted HCPCS codes, generating rejections that appear to be coder errors. This is a system maintenance task, not a coding education task.
The 2026 Guidehouse & HFMA RCM Trends Survey captures the clearest mid-year picture of where the industry stands: 78% of providers are using automation and AI to accelerate manual processes, yet denial rates are moving in the wrong direction. 20% of respondents now report denial rates exceeding 5% — up from 12% in the prior survey cycle. The practices most exposed are those that invested in AI tooling without simultaneously tightening front-end eligibility protocols.
| Metric | Industry Median | Top Quartile | Action Threshold |
|---|---|---|---|
| Days in A/R (Hospitals) | 38.3 days | 30.5 days | >50 days: critical |
| Days in A/R (Physician Practices) | 21.9 days | <18 days | >30 days: at risk |
| Clean Claim Rate | 95% | 98.5% | <90%: remediation |
| First-Pass Denial Rate | 8–10% | <5% | >15%: systemic |
| Cost to Collect | 3–5% of revenue | <2.5% | >7%: unsustainable |
CMS’s hospital price transparency enforcement shifted from “file existence” to “data quality” in 2026 — and the June 2026 enforcement action makes that shift explicit. More than 500 hospitals received CMS warning letters in June for failing to meet the updated data quality standards that took effect January 1, 2026.
Hospital price transparency data, when accurate, is being used by sophisticated payers and employer health plans to benchmark payment rates in commercial negotiations. Any practice negotiating commercial rates in 2027 will face counterparties who have accessed this data. Practices with ASC ownership or hospital-affiliated billing must ensure their machine-readable file compliance is current under the v3.0 schema or risk warning letters — and, eventually, civil monetary penalties.
CMS updated its civil monetary penalty policy: penalties are reduced by 35% when hospitals waive their right to an ALJ hearing except for violations of core requirements such as failing to publish the machine-readable file at all, or failing to include shoppable services data. Core violations carry the full penalty with no reduction available.
CMS released the 2026 CMS Interoperability Standards and Prior Authorization for Drugs Proposed Rule (CMS-0062-P), extending electronic prior authorization requirements from non-drug items and services (covered in the 2024 rule) to drug prior authorizations. The comment period closed June 15, 2026; finalization is expected in late 2026 with implementation targeted for 2027.
If CMS-0062-P is finalized in its current form, drug PA timelines compress significantly — which has real cash-flow consequences:
Oncology and rheumatology practices face the highest exposure to drug PA delays — infused agents like checkpoint inhibitors, ibrutinib, and biologic DMARDs are the most frequently delayed drug categories. If finalized, CMS-0062-P will force payers to make faster decisions on exactly these agents, which can materially improve cash flow for practices running high-cost drug panels.
The consolidation math is unambiguous: independent physicians now represent just 18% of the physician workforce — down from roughly one-third a decade ago. For the 18% who remain independent, the 2026 financial target is not growth — it is survival margin. Industry analysis shows practices need 6% or more in annual revenue growth just to maintain current margins against inflation and labor cost increases. Yet only 56% of medical group leaders reported revenue growth in 2025, and 30% reported a revenue decline.
| Metric | Target | Warning Zone | Critical Zone |
|---|---|---|---|
| Days in A/R | <21.9 days | 22–29 days | >30 days |
| First-Pass Denial Rate | <8% | 8–12% | >12% |
| Clean Claim Rate | >96% | 92–96% | <92% |
| Cost to Collect | <4% of net revenue | 4–6% | >6% |
| Annual Revenue Growth | 6%+ to hold margin | 3–5% (declining) | <3% (at risk) |
Payer contracting leverage favors large systems — but technology adoption is the equalizer. Practices running RCM with modern automation tools (real-time eligibility, automated claim scrubbing, AI denial prediction) achieve cost-to-collect ratios competitive with health systems, narrowing the administrative cost gap that drives consolidation decisions. The practices that stay independent are not the ones that try to out-negotiate a health system on rate — they are the ones that out-execute on billing efficiency.
If your independent practice has not benchmarked its Days in A/R, clean claim rate, and cost-to-collect against the HFMA MAP Keys targets above in the last 90 days, schedule that review for this month. In the current environment — 6% growth required just to hold ground, 30% of peers declining — operational blindspots in your revenue cycle are not recoverable with fee increases alone.
| Specialty | Key Update | Data Point |
|---|---|---|
| Primary Care | New Advanced Primary Care Management (APCM) G-codes live for 2026 — monthly add-on codes for non-face-to-face work: medication management, care coordination, complex follow-up | APCM represents meaningful per-patient monthly revenue for practices managing complex, chronically ill panels; if not billing APCM G-codes, uncaptured revenue accumulates every month |
| Cardiology | CY 2027 PFS proposed rule introduces new codes for AI-powered cardiac services: coronary atherosclerotic plaque assessment and cardiac risk analysis — first Category I CPT codes recognizing AI-assisted interpretation as separately billable; 2027 is ASM Year One | ASM (Ambulatory Specialty Model) is the first mandatory specialist accountability model in traditional Medicare; cardiology practices in ASM markets should begin roster verification now to ensure correct attribution |
| Orthopedics | 2026 bundling rule changes affect joint injection codes, arthroscopy procedures, and fracture care same-day billing; CY 2027 PFS same-day E/M + global bundling proposal (50% payment for lower-value service) adds further compression to multi-service encounters | Orthopedic practices routinely bill E/M visits alongside same-day procedural codes — model the 50% bundling revenue impact before the September 14 comment deadline |
| Oncology | Ibrutinib (Imbruvica) Medicare payment cut of 38% takes effect July 2026 under IRA drug negotiation provisions; ASCO updated its 340B policy statement (May 2026), proposing expanded 340B eligibility to independent oncology practices via a new Indigent Care Ratio formula | Drug costs = 60–80% of oncology practice revenue; 38% cut on a cornerstone CLL/MCL agent requires immediate alternative sourcing review; ASCO 340B expansion, if adopted, could partially offset via purchasing program access |
| Radiology | Six new Category I CPT codes (76014–76019) introduced for 2026 to assess implanted devices before MRI — covering cardiac devices, cochlear implants, neurostimulators, orthopedic hardware, and other metallic implants | Billable by the radiologist or supervising physician performing the compatibility assessment; a legitimate revenue expansion for imaging centers with growing implanted-device patient volume |
| Mental Health | Telehealth billing parity continues through 2026 pending Congressional action; POS 10 (telehealth in patient’s home) vs. POS 02 (other telehealth) coding must match payer-specific requirements — inconsistency remains a source of denials | Audio-only coverage and geographic waiver exceptions maintained at pandemic-era levels; verify payer-specific telehealth billing requirements quarterly — policies vary significantly by commercial payer |
| Gastroenterology | Follow-up colonoscopies after a positive stool test are now covered at 100% without patient cost-sharing; modifier –33 (preventive service) application when a diagnostic colonoscopy converts to therapeutic mid-procedure remains a billing complexity and source of patient complaints | Modifier –33 misapplication continues to generate unexpected patient bills and payer adjustments; audit this claim category in your denial reports and verify coder understanding of the conversion scenario |
The 38% ibrutinib (Imbruvica) payment cut is not prospective — it takes effect this month under the IRA’s Medicare drug price negotiation provisions. Oncology practices that purchase ibrutinib under buy-and-bill models need to verify their current acquisition cost against the new Medicare payment rate immediately. If the payment rate has dropped below acquisition cost, the practice is absorbing a loss on every vial administered under the old purchasing arrangement.
Seven specific moves, prioritized by urgency and deadline. The September 14 comment deadline for the CY 2027 PFS is the longest-fuse item that requires the most lead time.